跳到正文
原文
MedPage Today·· 7 天前精选AI 评分75

Dazodalibep III期试验显示对干燥综合征的主要终点获益

Novel Sjogren's Drug Passes First Phase III Test

AI 导读

一种在研CD40L拮抗剂dazodalibep的一项48周III期随机试验以ESSDAI为主要终点,3000 mg每12周和1500 mg每4周两组在 week 48 分别较基线下降5.2分和5.6分,安慰剂下降3.8分;高危患者中有半数高剂量组达到7分下降,安全性整体可接受,严重不良事件少于安慰剂组。该试验由Amgen主导并在美国风湿病学会会议上公布,另一项III期试验尚未完成。

推荐理由

一次III期试验的具体疗效与安全性数据,读者可了解候选药物对干燥综合征的真实改善幅度及潜在风险特征。

正文

— Barring catastrophe in second trial, approval seems likely

by John Gever, Contributing Writer, MedPage Today

November 12, 2026 • 3 min read

ORLANDO -- An investigational CD40L antagonist called dazodalibep looks to be nearing the finish line on the way to approval for Sjögren's disease, based on results from a 48-week phase III trial reported here.

With scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) as the randomized trial's primary outcome measure, patients on the active drug saw reductions of 5.2 and 5.6 points by week 48, depending on which of two doses they received, compared with a 3.8-point decline with placebo (P<0.05 and P<0.001, respectively), reported Ghaith Noaiseh, MD, of the University of Kansas in Kansas City.

Clinically significant reductions of 3 points were achieved by about two-thirds of patients receiving dazodalibep; fewer met more stringent response levels, but even so, fully half of patients on the higher of the two doses had ESSDAI scores drop by 7 points, Noaiseh said during a late-breaking abstract session at the American College of Rheumatology annual meeting. Despite a strong placebo response in the trial, the drug held a statistically significant advantage.

In addition, safety findings were better than unremarkable, with fewer serious adverse events than were seen with placebo.

This was one of a pair of phase III trials conducted by drugmaker Amgen, which took control of dazodalibep when it bought the original developer, Horizon Therapeutics, in 2023. The other has not been completed but should be soon, the company has said. These studies follow encouraging results from phase II trials reported in 2023.

Dazodalibep is intended to disrupt interaction between the CD40 receptor and its ligand, CD40L, which should have a wide range of effects, Noaiseh explained. It "disrupts CD40L-mediated costimulatory interactions between T cells, B cells, glandular epithelial cells, and other antigen-presenting cells," he said. That leads to decreased production of inflammatory mediators as well as autoantibodies.

Also of note, although it's a biologic drug, it's not a monoclonal antibody -- rather, it's a fusion product based on an antibody but with the Fc portion removed, Noaiseh said, noting that previous efforts to target CD40L with an antibody led to unacceptably high rates of thrombosis.

For this first phase III study, the investigators enrolled 648 Sjögren's disease patients, randomizing them to three arms: placebo, dazodalibep 3,000 mg every 12 weeks (low dose), or the drug at 1,500 mg every 4 weeks (high dose). Their mean age was 53, and 94% were women. Some 56% were from Europe and North America, 7% from Japan, and the rest from a variety of other countries.

Baseline ESSDAI scores averaged 10.2, with about 20% having scores of 14 or higher, indicating high activity. A key secondary outcome measure was the EULAR Sjögren's Syndrome Patient-Reported Index (ESSPRI); scores at baseline averaged 7.07. Another outcome that was developed specially for these trials was a Diary for Assessing Sjögren's Patients Index (DASPRI), in which patients recorded their symptoms daily, including dryness at four separate body locations -- a complement to ESSPRI, which asks patients about symptoms during the previous 2 weeks and only rates overall dryness.

In general, the higher dazodalibep dose was more effective. This was most clearly seen in data on dryness, with a decrease of 2.5 points on ESSPRI's dryness domain, and a 1.98-point decrease in DASPRI dryness -- compared with -1.33 and -1.05 with placebo, respectively (P<0.001 for both comparisons). Dryness relief with the lower drug dose came in about halfway between the high dose and placebo, missing statistical significance.

Overall rates of treatment-emergent adverse events were similar across all three arms, affecting some 85% of patients. Those considered treatment-related were a bit more common with the high-dose drug (37% vs 25% for placebo), but only five events were rated as serious in the entire study sample, two of which were in the placebo group. Likewise, discontinuations because of adverse events were about the same in the three arms, with 24 total among the 648 participants.

The investigators also examined "special interest" events that could potentially arise from this novel biologic agent targeting a range of immune functions. These included allergic and hypersensitivity reactions, thromboembolism, opportunistic infections, and various malignancies. There were very few of any of these, and none were more common with either dazodalibep dose versus placebo. In total, 40 such events were seen, including 14 with placebo, 12 in the low-dose group, and 14 with the high dose.

来源:MedPage Today · medpagetoday.com